Explore 2026 options for steroid-refractory chronic GVHD: four FDA-approved agents, key trial evidence, and where ECP fits in care.
Brooke Adams, PharmD
Advertisement
Articles by Brooke Adams, PharmD
Experts detail how steroid-refractory chronic GVHD care now uses targeted therapies and personalized choices, weighing organs, side effects, and infusion logistics.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Savolitinib Plus Osimertinib NDA Submitted to FDA for MET-Driven, EGFR-Mutated NSCLC After EGFR TKI
2
Daraxonrasib Approval Signals a New Era for RAS-Targeted Therapy in Pancreatic Cancer
3
Cilta-Cel Shows Long-Term Treatment-Free Remissions in Lenalidomide-Refractory Myeloma
4
Researchers Uncover How Aggressive Breast Cancer May Spread to the Brain
5